Cargando…

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies

Treatment with the demethylating agent 5-Azacytidine leads to prolonged survival for patients with myelodysplastic syndrome, and the demethylation induces upregulation of cancer-testis antigens. Cancer-testis antigens are well-known targets for immune recognition in cancer, and the immune system may...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gang, A O, Frøsig, T M, Brimnes, M K, Lyngaa, R, Treppendahl, M B, Grønbæk, K, Dufva, I H, Straten, P thor, Hadrup, S R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2014
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3972700/ https://www.ncbi.nlm.nih.gov/pubmed/24681961 http://dx.doi.org/10.1038/bcj.2014.14

Ejemplares similares

Comment on “5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity”
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Broadening the repertoire of melanoma-associated T-cell epitopes
por: Frøsig, Thomas Mørch, et al.
Publicado: (2015)

Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation
por: Ørskov, Andreas D., et al.
Publicado: (2015)

P29. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors
por: Lyngaa, L, et al.
Publicado: (2014)

Discovery of CD8 T cell epitopes in Merkel cell polyomavirus through combinatorial encoding with MHC multimers
por: Lyngaa, Rikke, et al.
Publicado: (2013)

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
por: Bogenberger, J M, et al.
Publicado: (2014)

High frequency of T cells specific for cryptic epitopes in melanoma patients
por: Andersen, Rikke Sick, et al.
Publicado: (2013)

Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment
por: Hadrup, Sine, et al.
Publicado: (2012)

Azacytidine impairs NK cell activity in AML and MDS patients undergoing MRD-based pre-emptive treatment after allogeneic stem cell transplantation
por: Schönefeldt, C, et al.
Publicado: (2013)

Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line
por: Aumer, Tina, et al.
Publicado: (2022)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

PB1998: AZACYTIDINE AND ALLOGENOUS STEM CELL TRANSPLANTATION IN LATE-ONSET ERYTHROPOIETIC PROTOPORPHYRIA
por: Fassi, Daniel El, et al.
Publicado: (2023)

Natural Killer Cells in Myeloid Malignancies: Immune Surveillance, NK Cell Dysfunction, and Pharmacological Opportunities to Bolster the Endogenous NK Cells
por: Carlsten, Mattias, et al.
Publicado: (2019)

Cell biological steps and checkpoints in accessing NK cell cytotoxicity
por: Mace, Emily M, et al.
Publicado: (2014)

Synthesis and Antiproliferative Activities of 5-Azacytidine Analogues in Human Leukemia Cells
por: Guo, Gang, et al.
Publicado: (2008)

5-Azacytidine-Mediated Modulation of the Immune Microenvironment in Murine Acute Myeloid Leukemia
por: Ebelt, Nancy D., et al.
Publicado: (2022)

Cytogenetic effect of 5-azacytidine in patients with hematological malignancies
por: Tsuda, Jessica Romy, et al.
Publicado: (2011)

Azacytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy
por: Iluta, Sabina, et al.
Publicado: (2021)

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia
por: Tibes, Raoul, et al.
Publicado: (2015)

Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity
por: van Beek, Jasper J. P., et al.
Publicado: (2016)

The use of 5-azacytidine in pregnant patient with Acute Myeloid Leukemia (AML): a case report
por: Alrajhi, Abdullah M., et al.
Publicado: (2019)

“Immunotherapy of cancer: present status and future promise”: Danish Cancer Society Symposium, Copenhagen, Denmark, 23rd–25th September 2013
por: Donia, Marco, et al.
Publicado: (2014)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

Azacytidine sensitizes acute myeloid leukemia cells to arsenic trioxide by up-regulating the arsenic transporter aquaglyceroporin 9
por: Chau, David, et al.
Publicado: (2015)

Human endogenous retroviruses form a reservoir of T cell targets in hematological cancers
por: Saini, Sunil Kumar, et al.
Publicado: (2020)

Cytotoxic Effects of 5-Azacytidine on Primary Tumour Cells and Cancer Stem Cells from Oral Squamous Cell Carcinoma: An In Vitro FTIRM Analysis
por: Notarstefano, Valentina, et al.
Publicado: (2021)

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer
por: Leung, Elaine Y.L., et al.
Publicado: (2020)

Cysteine Cathepsins as Regulators of the Cytotoxicity of NK and T Cells
por: Perišić Nanut, Milica, et al.
Publicado: (2014)

Alterations of immune response of non-small cell lung cancer with Azacytidine
por: Wrangle, John, et al.
Publicado: (2013)

Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia
por: Wang, Yanyu, et al.
Publicado: (2022)

Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2017)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

NK Cell Interaction With Platelets and Myeloid Cells in the Tumor Milieu
por: Maurer, Stefanie, et al.
Publicado: (2020)

Correction: Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma
por: Bjoern, Jon, et al.
Publicado: (2018)

NK Cells in the Treatment of Hematological Malignancies
por: Gonzalez-Rodriguez, Ana P, et al.
Publicado: (2019)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

Dominant cytotoxic NK cell subset within CLPD-NK patients identifies a more aggressive NK cell proliferation
por: Barilà, Gregorio, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_ukssdgv72pp51ptkt3qddf4c3t